Clinical treatment for hepatitis C reverses CYP2C19 inhibition (2021)
- Authors:
- USP affiliated authors: ROCHA, ADRIANA - FCFRP ; LANCHOTE, VERA LUCIA - FCFRP ; PIPPA, LEANDRO FRANCISCO - FCFRP
- Unidade: FCFRP
- DOI: 10.1111/bcp.14829
- Subjects: ANTIVIRAIS; CITOCROMO P-450; FLAVIVIRIDAE; HEPATITE C; HEPATITE CRÔNICA; FARMACOTERAPIA
- Keywords: CYP2C19; HCV treatment; Hepatitis C; Metabolic ratio; Omeprazole
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: West Sussex
- Date published: 2021
- Source:
- Título do periódico: British Journal of Clinical Pharmacology
- ISSN: 0306-5251
- Volume/Número/Paginação/Ano: v. 87, n. 10, p. 4013-4019, 2021
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
PIPPA, Leandro Francisco et al. Clinical treatment for hepatitis C reverses CYP2C19 inhibition. British Journal of Clinical Pharmacology, v. 87, n. 10, p. 4013-4019, 2021Tradução . . Disponível em: https://doi.org/10.1111/bcp.14829. Acesso em: 04 maio 2024. -
APA
Pippa, L. F., Vieira, C. P., Caris, J. A., Rocha, A., Garcia, C. P., Rezende, R. E. F., & Lanchote, V. L. (2021). Clinical treatment for hepatitis C reverses CYP2C19 inhibition. British Journal of Clinical Pharmacology, 87( 10), 4013-4019. doi:10.1111/bcp.14829 -
NLM
Pippa LF, Vieira CP, Caris JA, Rocha A, Garcia CP, Rezende REF, Lanchote VL. Clinical treatment for hepatitis C reverses CYP2C19 inhibition [Internet]. British Journal of Clinical Pharmacology. 2021 ; 87( 10): 4013-4019.[citado 2024 maio 04 ] Available from: https://doi.org/10.1111/bcp.14829 -
Vancouver
Pippa LF, Vieira CP, Caris JA, Rocha A, Garcia CP, Rezende REF, Lanchote VL. Clinical treatment for hepatitis C reverses CYP2C19 inhibition [Internet]. British Journal of Clinical Pharmacology. 2021 ; 87( 10): 4013-4019.[citado 2024 maio 04 ] Available from: https://doi.org/10.1111/bcp.14829 - Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: estimation of doxorubicin hepatic extraction ratio
- Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers
- Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia
- Detection of allopurinol and oxypurinol in canine urine by HPLC/MS-MS: focus on veterinary clinical pharmacokinetics
- Omeprazole inhibits preferentially the metabolism of the (+)-(S)-citalopram eutomer in healthy volunteers
- Farmacocinética, metabolismo e excreção renal da doxorrubicina em pacientes com câncer de mama
- Influência da hepatite C crônica na atividade das principais isoformas do citocromo P450 e transportadores de membranas em pacientes com diferentes graus de fibrose hepática
- Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers
- UPLC-MS/MS method for gemfibrozil determination in plasma with application to a pharmacokinetic study in healthy Brazilian volunteers
- Pharmacokinetics of venlafaxine enantiomers and their metabolites in psoriasis patients
Informações sobre o DOI: 10.1111/bcp.14829 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas